Non-viral platforms have until recently been applied to the delivery of mRNA encoding neoantigens. Multiple clinical trials investigating the safety and efficacy of mRNA vaccine encoding neoantigens are ongoing (TableΒ 3). Moderna and Merck collaborated to develop mRNA-5671, a Kras personalized vaccine (encoding KRAS neoantigens), alone or in together with Merck’s PD-1 specific antibody KEYTRUDA (Pembrolizumab) to treat patients with pancreatic cancer in Phase I Trial [145]. LNPs were utilized to deliver mRNA-5671 intramuscularly every 3 weeks, 9 cycles in total. Results suggested that anti-tumoral immune response was developed and the formulation is overall well-tolerated. Another product is mRNA-4157, a personalized vaccine encapsulated in LNPs, for treating patients with resected solid tumors including melanoma, bladder carcinoma and NSCLC, as monotherapy or in combination with pembrolizumab (NCT03313778). The mRNA-4157 based mono and combination therapy with pembrolizumab showed an acceptable safety profile along with remarkable neoantigen-specific T cell responses. Twelve out of thirteen patients treated by monotherapy were reported to be disease-free [148]. BioNtech collaborated with Genentech to join the campaign and to evaluate the safety and efficacy of mRNA personalized vaccine, RO7198457 delivered by Lipo-MERIT platform in multiple phase I and II clinical trials.

λͺ¨λ”λ‚˜μ—μ„œλŠ” mRNA-4157μ΄λž‘ mRNA-5671 이 λ‘κ°œμ˜ μ•” 백신을 μž„μƒ μ‹œν—˜ν•˜κ³  있음.
μ „μžλŠ” 개인맞좀 μ•” λ°±μ‹ μœΌλ‘œ μœ„μ•” μœ λ°©μ•” 폐암 λ“±λ“±λ“± λͺ¨λ“  κ³ ν˜•μ•”μ„ λŒ€μƒμœΌλ‘œ μ‹œν—˜μ€‘μ΄κ³  μž„μƒ 2μƒκΉŒμ§€ μ›ν™œνžˆ μ§„ν–‰μ€‘μž„.
ν›„μžλŠ” KRASλΌλŠ” 인자의 변이λ₯Ό ν‘œμ μœΌλ‘œ ν•˜λŠ” 백신이고 KRASλŠ” 전체 μ•”ν™˜μžμ˜ 20% 이상, 특히 췌μž₯μ•”μ΄λ‚˜ 폐암, λŒ€μž₯μ•” ν™˜μžμ—μ„œ 많이 λ‚˜μ˜€λŠ” λŒμ—°λ³€μ΄ 인자라 이μͺ½μ„ νƒ€κ²Ÿν•˜κ³  있음 특히 췌μž₯μ•”. μ–˜λŠ” μž„μƒ 1μƒμ€‘μž„.
λ˜ν•œ 이 λ°±μ‹ λ§Œ λ„£λŠ”κ²Œ μ•„λ‹ˆλΌ κ·Έ 유λͺ…ν•œ 머크 μ‚¬μ˜ λ©΄μ—­κ΄€λ¬Έμ–΅μ œμ œ(PD-1 μ–΅μ œμ œ λ©΄μ—­ν•­μ•”μ œ) ν‚€νŠΈλ£¨λ‹€λž‘ 같이 νˆ¬μ—¬ν•˜λŠ” λ³‘μš© μž„μƒμ„ ν•˜κ³  있음.

λ…Όλ¬Έμ—μ„œ κ½€λ‚˜ μœ μ˜λ―Έν•œ κ²°κ³Όκ°€ λ³΄μ˜€λŠ”λ°
mRNA-5671은 μž„μƒ 1상이 아직 진행쀑이라 ν™•μ‹€ν•œ κ²°κ³Ό λ°œν‘œλŠ” μ—†μ—ˆμ§€λ§Œ μž„μƒμ—μ„œ 췌μž₯μ•” 4κΈ° ν™˜μžμ—κ²Œ νˆ¬μ—¬ν–ˆμ„λ•Œ(λ”°λ‘œ μ°Ύμ•„λ³΄λ‹ˆ 췌μž₯μ•” 4κΈ° ν™˜μžλ§Œ μž„μƒ μ‹œν—˜ λͺ¨μ§‘을 ν–ˆμŒ) ν•­μ’…μ–‘ λ©΄μ—­ λ°˜μ‘μ΄ μƒμ„±λ˜λŠ”λ° μ„±κ³΅ν–ˆλ‹€κ³  함.
제일 μ€‘μš”ν•œκ±΄ 개인맞좀 μ•” 백신인 mRNA-4157인데
치료 받은 ν™˜μž 13λͺ… 쀑 12λͺ…이 무병 μƒνƒœλΌκ³  함
암쒅은 μ•ˆ λ‚˜μ™€ μžˆλŠ”λ° 흑색쒅, λ°©κ΄‘μ•”, λΉ„μ†Œμ„Έν¬ 폐암 λ“± μ–˜κΈ° λ‚˜μ˜€λŠ”κ±Έ 봐선 이런 암듀에 κ±Έλ¦° μ‚¬λžŒλ“€μ΄ ꡬ뢄 없이 치료 받은듯 함. μ• μ΄ˆμ— νƒ€κ²Ÿμ΄ μ•”μ’… ꡬ뢄 없이 κ³ ν˜•μ•”μ΄λΌ.

2017년도에 첫발 λ—€ 졜초이자 초기 mRNA μ•” 백신인데도 μ—„μ²­λ‚œ κ²°κ³Όμž„.

- dc official App